Clinical trials
Advanced Solid Tumor clinical trials
Below are recruiting advanced solid tumor clinical trials, each written for real people, not researchers. We’re tracking 1,391 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06990464RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial is testing an investigational drug called SIBP-A19 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
Fuzhou, FujianAges 18–75 - NCT07299747RecruitingPhase 1/Phase 2
Study of VBC103 for advanced solid tumors
This trial tests a new drug, VBC103, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink or slow the growth of these tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06170294RecruitingPhase 1
MAGE-A4 TCR-T therapy for advanced solid tumors
This trial tests a new type of immune therapy called MAGE-A4-directed TCR-T. It uses your own immune cells (T cells) that are modified to find and attack cancer cells that have a specific protein (MAGE-A4). It is for people with advanced solid tumors who have already tried other treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT06173219RecruitingPhase 1/Phase 2
Radiation and immunotherapy for advanced cancer
This trial tests combining two types of radiation therapy with an immunotherapy drug for people with advanced solid tumors that have spread or come back. The goal is to see if this approach can help when standard treatments have stopped working or aren’t an option.
Beijing, Beijing MunicipalityAges 18–75 - NCT07069062RecruitingPhase 1/Phase 2
Study of HY0001a for Advanced Solid Tumors
This trial tests a new drug, HY0001a, for people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein on some cancer cells, and the study aims to find the right dose and see if it helps shrink tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT06143774RecruitingPhase 1
Study of TRX-920 for advanced solid tumors
This trial tests a new drug called TRX-920 for people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The goal is to see if TRX-920 is safe and effective.
TaichungAges 18–100 - NCT06126666RecruitingPhase 1
ABL103 for advanced solid tumors
This trial tests a new drug called ABL103 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective.
Seongnam, SeoulAges 18 years+ - NCT06619587RecruitingPhase 1
Study of GDC-7035 for advanced solid tumors with KRAS G12D
This trial tests a new oral drug (GDC-7035) for people with advanced solid tumors that have a specific KRAS mutation (G12D). The drug may be given alone or with other treatments to see if it is safe and helps fight the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT06094556RecruitingPhase 1
A study of SHR-1826 for advanced solid tumors
This trial tests a new drug called SHR-1826 for people with advanced solid tumors that have not responded to or are no longer helped by standard treatments. It is an early-phase study (Phase 1) to see if the drug is safe and how well it works.
Guangzhou, GuangdongAges 18–75 - NCT05835609RecruitingPhase 1
PM534 IV treatment for advanced solid tumors
This early-phase study tests PM534 given through an IV to see if it is safe and how well it works in people with advanced solid tumors. It may help by finding a new treatment option, but eligibility is strict to protect participants from side effects.
BarcelonaAges 18 years+ - NCT07601243RecruitingPhase 1
GS-2426 for advanced solid tumors with MTAP deficiency
This study tests a new drug called GS-2426 for people with advanced solid tumors that have a specific genetic change called MTAP deficiency. It may be an option if other treatments have stopped working or are not available.
Grand Rapids, MichiganAges 18 years+ - NCT06428331RecruitingPhase 1
Study of SKB518 for advanced solid tumors
This trial tests a new drug called SKB518 for people with advanced solid tumors that have stopped responding to standard treatments or cannot receive them. The goal is to see if SKB518 can help shrink or control the tumor.
Shanghai, ChinaAges 18 years+ - NCT07251166RecruitingPhase 1
Safety study of GenSci140 for advanced solid tumors
This trial tests a new drug, GenSci140, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and how well it works.
Shenyang, LiaoningAges 18–75 - NCT06404528Recruiting
Low-dose chemo under low blood sugar for advanced solid tumors
This trial tests whether giving low-dose chemotherapy while your blood sugar is low can help treat advanced solid tumors that have stopped responding to standard treatments. It aims to see if this approach is safe and effective.
Wuxi, JiangsuAges 18–75 - NCT06234098RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors
This trial tests a new drug called AT-1965 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and if it can shrink tumors.
Scottsdale, ArizonaAges 18 years+ - NCT07021534RecruitingPhase 1
CAR-NK and CAR-T cells for cancer with liver spread
This trial tests a new treatment that uses special immune cells (CAR-NK and CAR-T cells) given directly into the liver artery, then through a vein, to fight advanced solid tumors that have spread to the liver. It is for people who have already tried standard treatments and need new options.
Hangzhou, ZhejiangAges 18–75 - NCT07229898RecruitingPhase 1
GEN-725 tablets for advanced solid tumors
This trial tests a new tablet called GEN-725 for people with advanced solid tumors that have stopped responding to standard treatments or cannot tolerate them. It aims to see if the drug is safe and how it affects the body, and may be an option if you've had prior treatment with PD-1/PD-L1 inhibitors that stopped working at least 6 months ago.
HarbinAges 18–75 - NCT06490068RecruitingPhase 2
LTC004 with toripalimab for immunotherapy-resistant solid tumors
This trial tests a new combination of two drugs (LTC004 and toripalimab) for people with advanced solid tumors that have stopped responding to standard immunotherapy. It aims to see if this combination can help when immunotherapy alone no longer works.
BeijingAges 18–75 - NCT06512116RecruitingPhase 1
Testing SIBP-A17 for advanced solid tumors with HER2
This trial tests a new drug called SIBP-A17 for advanced solid tumors that have not responded to other treatments. It focuses on tumors that have a protein called HER2, and the goal is to see if the drug is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT04064359RecruitingPhase 1
Safety study of OBT076 for certain CD205+ solid tumors
This Phase 1 trial tests the safety of a new drug called OBT076 and looks for early signs it can help people with certain advanced (recurrent or metastatic) solid tumors that have a specific marker called CD205. You may be eligible if standard treatments are not available or no longer work, and your cancer meets lab and scan requirements.
Phoenix, ArizonaAges 18 years+ - NCT07648472RecruitingPhase 1
Safety and efficacy of OVV-01 injection for advanced solid tumors
This study tests a new cancer treatment called OVV-01 that is injected directly into tumors or given through the vein. It's for patients with advanced solid cancers (like melanoma, lung, breast, or colon cancer) who have already tried at least two standard treatments without success.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07192107RecruitingPhase 1/Phase 2
Study of MHB042C for advanced solid tumors
This trial tests a new drug called MHB042C for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective.
Guangzhou, GuangdongAges 18 years+ - NCT06349811RecruitingPhase 1
Study of BL-M05D1 for advanced solid tumors
This study tests a new drug called BL-M05D1 for people with advanced or metastatic solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT05434234RecruitingPhase 1/Phase 2
Study drug YL201 for advanced solid tumors
This trial tests YL201 in people with advanced (late-stage) solid cancers when usual treatments don’t work or can’t be tolerated. The study looks at how the treatment is given, how safe it is, and how well it can shrink tumors.
Fair Oaks, CaliforniaAges 18 years+
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced solid tumor?
- Yes. Clin2 currently lists 1,391 recruiting advanced solid tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced solid tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced solid tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.